NEW YORK (AP) – Forest Laboratories Inc. said that regulators will take another three months to review its respiratory disease drug candidate aclidinium.
Forest said the Food and Drug Administration now expects to make a decision on aclidinium in July instead of April. The company did not give a reason for the extension.
In February, an FDA advisory panel recommended that aclidinium be approved as a maintenance treatment for chronic obstructive pulmonary disease. Forest is developing the drug through a partnership with Spanish drugmaker Almirall SA.
Date: March 29, 2012
Source: Associated Press
Filed Under: Drug Discovery
